What is the appropriate pediatric dose of terlipressin?

Terlipressin Pediatric Dosing

There is no FDA-approved pediatric dose for terlipressin, as all regulatory approval and formal dosing guidelines are based exclusively on adult data for hepatorenal syndrome. However, based on limited pediatric case series and off-label use, a loading dose of 20 mcg/kg IV bolus followed by continuous infusion at 4-20 mcg/kg/hour has been reported in critically ill children 1, 2.

Critical Context

The FDA label for terlipressin (TERLIVAZ) provides no pediatric dosing information 3. All clinical trials establishing efficacy were conducted in adults with hepatorenal syndrome type 1 (HRS-1), with the standard adult regimen being 1 mg (0.85 mg terlipressin base) IV every 6 hours, escalating to 2 mg (1.7 mg base) every 6 hours if inadequate response by day 4 3.

Pediatric Off-Label Experience

Reported Dosing Strategies

The most comprehensive pediatric data comes from case series in critically ill children:

• Loading dose: 20 mcg/kg IV bolus 1, 4
• Maintenance: Continuous infusion at 4-20 mcg/kg/hour, titrated upward by 1 mcg/kg/hour increments to maintain age-appropriate mean arterial pressure 1
• Alternative bolus dosing: 20 mcg/kg every 4 hours has been used in cardiac arrest scenarios 4

In a series of 16 children (newborn to 15 years) with catecholamine-resistant septic shock, the median infusion rate was 5.2 mcg/kg/hour (range 3.8-6.7) 1. A more recent review of 21 terlipressin administrations in 16 children with liver disease found similar dosing with median 5.2 mcg/kg/hour 2.

Clinical Indications in Pediatrics

Published pediatric cases have used terlipressin for:

1. Refractory septic shock (most common) - when high-dose catecholamines fail 1, 5
2. Hepatorenal syndrome in liver disease 2, 6
3. Cardiac arrest (rescue therapy after failed epinephrine) 4
4. Portal hyperperfusion post-liver transplant 6

Safety Considerations

Ischemic complications are the primary concern. In the pediatric septic shock series, 8 patients had ischemia at admission, and terlipressin induced reversible ischemia in 4 additional patients (25% drug-related ischemia rate) 1. Risk factors for mortality included meningococcal infection, pre-existing ischemia, and lower mean arterial pressure 1.

Contraindications (Extrapolated from Adult Data)

• Active ischemia (coronary, peripheral, mesenteric) 7
• Hypoxia or worsening respiratory symptoms 7
• Baseline severe hypoxemia (FDA warning for ACLF-3 with respiratory failure in adults) 8

Monitoring Requirements

• Continuous blood pressure monitoring
• Vigilant assessment for digital/extremity ischemia or cyanosis 2
• Cardiac function (risk of afterload increase in underlying cardiomyopathy) 8
• Gastrointestinal symptoms (abdominal pain, diarrhea from intestinal motility stimulation) 8, 2

Critical Caveats

This is entirely off-label use with no controlled pediatric trials. The evidence base consists of:

• Small case series (largest n=16) 1, 2
• Single case reports 5, 9, 6
• No randomized controlled trials in children
• No pharmacokinetic studies in pediatric populations

The adult FDA approval specifically excludes pediatric indications 3. Adult guidelines recommend octreotide as the vasoactive drug of choice for variceal hemorrhage due to terlipressin's inferior safety profile 7, and this safety concern is amplified in children given the lack of dosing data.

Practical Approach

If considering terlipressin in a critically ill child (consultation with pediatric critical care and/or hepatology is mandatory):

1. Confirm refractory shock - failure of high-dose catecholamines (typically norepinephrine >2 mcg/kg/min) 1
2. Exclude contraindications - particularly pre-existing ischemia, severe hypoxemia
3. Start conservatively: 20 mcg/kg IV bolus, then 4 mcg/kg/hour continuous infusion 1, 2
4. Titrate cautiously: Increase by 1 mcg/kg/hour increments based on MAP response, up to maximum 20 mcg/kg/hour 1
5. Monitor intensively: Continuous hemodynamics, serial perfusion assessments, watch for ischemic complications

The median treatment duration in pediatric series was relatively short (specific duration not detailed but implied to be days, not weeks) 2, consistent with adult data showing median 5-day treatment 3.

Given the absence of regulatory approval, lack of controlled trials, and significant ischemic risk, terlipressin should be reserved for truly refractory situations where conventional therapies have failed and used only in centers with pediatric intensive care expertise.